Introduction
There are two people named Matthew Schissler in online searches, and that confusion has led to wrong details on some websites. This article focuses on Matthew L. Schissler, the American entrepreneur, biotech founder, and private investor connected with stem cell banking, advertising, and small-cap investment management.
To understand Matthew Schissler net worth in 2026, you need more than random online estimates. This guide breaks down his real business background, Cord Blood America’s role, private investment activity, advisory work, board positions, and available public records to give a clearer view of his life, career, and wealth.
Matthew Schissler Life Story
Matthew Schissler, also known as Matthew L. Schissler, is an American entrepreneur, investor, and business executive best known for founding Cord Blood America in 2003. His public profile grew mainly through Cord Blood America, where he combined healthcare, capital raising, and acquisition-led growth. During his leadership, the publicly listed healthcare and biotech firm reportedly secured more than $30 million in funding, completed five major acquisitions, and expanded its operations into South America.
Beyond Cord Blood America, Schissler has worked across small-cap and mid-cap companies in healthcare, advertising, consumer products, and aviation. He also earned recognition as an Ernst and Young Entrepreneur of the Year semi-finalist in Los Angeles, but his story is less about fame and more about long-term business strategy, smart timing, and disciplined wealth building.
Matthew Schissler Profile Summary
| Detail | Information |
| Full Name | Matthew L. Schissler |
| Date of Birth | June 9, 1971 |
| Age in 2026 | 54 years old |
| Current Locations | Fort Lauderdale, Florida, and Paradise Valley, Arizona |
| Education | BA in Biology and Public Policy from St. Mary’s College of Maryland, 1993 |
| Securities Licenses | Series 63 and Series 79 |
| Career Beginning | Started in sales at Delmarva Broadcasting |
| Early Career Role | Senior Regional Director at TMP Worldwide from 1994 to 2001 |
| First Company Founded | RainMakers International, a direct response advertising company, was founded in 2001 |
| Major Company | Cord Blood America Inc. (CBAI, OTCBB), founded in 2003 |
| CBAI Leadership Role | Chairman and CEO from 2003 to 2012 |
| Capital Raised at CBAI | More than $30 million |
| Major CBAI Acquisitions | CorCell Inc., Cryobank for Oncologic and Reproductive Donors, and BioCells Argentina |
| Award Recognition | Ernst and Young Entrepreneur of the Year, Los Angeles semi-finalist, 2008 |
| Current Firms | Work Your Core Investments LLC and Pyrenees Investments LLC |
| Board Roles | Aztec Airways Inc., Big League Wiffle Ball, and IIOT-OXYS Inc. |
| GHS Ownership | Approximately 33% stake |
| Other Companies | Frozen Food Gift Group (FROZ, 2009) and China Stem Cells Inc. |
| Estimated Net Worth in 2026 | $5 million to $10 million |
Matthew Schissler Early Life and Education
Matthew Schissler was born on June 9, 1971, and studied at St. Mary’s College of Maryland from 1989 to 1993, where he earned a Bachelor of Arts in Biology and Public Policy. This mix of science and policy later became important in his business career, especially when he entered the healthcare and biotechnology space. Biology helped him understand cord blood stem cells, medical preservation, and the science behind biotech work, while Public Policy gave him a clearer view of healthcare rules, governance, and regulation.
That background helped him build Cord Blood America with more credibility because he could understand both the scientific side and the business side of a highly regulated industry. His education was not just a degree; it became part of the foundation behind his leadership, decision-making, and early advantage in the cord blood banking field.
Matthew Schissler Career Start and Sales Background
Matthew Schissler began his career in sales after graduating from St. Mary’s College in 1993, first working at Delmarva Broadcasting, a regional radio and media company. That early media sales role helped him build communication skills, direct-to-consumer experience, and confidence in persuasion-based business. From 1994 to 2001, he worked at TMP Worldwide Inc., a major staffing and advertising company active in executive search, recruitment advertising, and early internet-based hiring platforms.
During those seven years, he held sales and management roles, eventually rising to Senior Regional Director. His work involved client relationships, team building, revenue targets, and managing business operations during the dot-com era. This experience gave him the commercial foundation, leadership discipline, and business-building mindset he later used when starting his own companies.
Matthew Schissler’s First Business Venture
Matthew Schissler’s first business venture began in April 2001, after he left TMP Worldwide and founded RainMakers International, a direct response advertising agency. He served as President and CEO of the company from the company’s founding until January 2003, giving him direct experience in ownership, agency management, and business development. RainMakers focused on marketing campaigns designed to create immediate and measurable audience responses, which required both creative execution and strong performance analysis.
During this period, Schissler managed client relationships, campaign results, creative output, and daily agency operations. Although he ran RainMakers for about two years, the experience helped him build practical leadership, client management, and business growth skills before a new opportunity moved him toward his next major chapter with Cord Blood America.
Matthew Schissler and Cord Blood America
Matthew Schissler co-founded Cord Blood America Inc., commonly known as CBAI, in January 2003. The healthcare and biotechnology company became the most important chapter of his career, shaping his public business profile and long-term career growth. Schissler served as Chairman of the Board and Chief Executive Officer from the company’s beginning until 2012, giving him nearly nine years of leadership experience. His role at Cord Blood America showed his ability to lead a public company, manage corporate development, and build credibility in the healthcare business.
What Is Cord Blood Banking?
Cord blood banking is the process of collecting and storing blood left in the umbilical cord and placenta after a baby is born. This blood contains stem cells that may be used in future medical treatments for certain cancers, blood disorders, and immune system deficiencies. In 2003, when Matthew Schissler built Cord Blood America, this idea was still new to many families and not yet part of mainstream healthcare decisions.
Most expectant parents had little awareness of the service, and the market was still small, fragmented, and without a dominant leader. Schissler saw that gap early and turned cord blood banking into a business opportunity by building a company around a clear future healthcare need.
Matthew Schissler and CBAI’s Acquisition Growth
Matthew Schissler did not grow CBAI only through slow organic expansion. He used acquisitions to increase the company’s storage capacity, client base, infrastructure, and market position in the private cord blood banking industry. In 2005, CBAI absorbed Cord Partners Inc., which helped strengthen its private family stem cell banking services. In 2006, the company acquired assets from Cryobank for Oncologic and Reproductive Donors, adding about 750 umbilical cord blood samples and cryogenic storage infrastructure.
CBAI also acquired CorCell Inc., then one of the largest cord blood banks in the United States, which helped move the company from a smaller player toward a stronger industry position. Schissler also expanded beyond the U.S. by establishing BioCells Argentina as a South American subsidiary, showing that he saw cord blood banking as a global healthcare opportunity.
Across his time at CBAI, Schissler raised more than $30 million to support five asset acquisitions, two stock purchases, and three minority investments. For a small-cap public company in a niche healthcare sector, that was a serious achievement because it required investor trust, a clear business story, public company reporting, and compliance discipline.
Since CBAI traded on the OTCBB under the ticker symbol CBAI, its growth depended not only on acquisitions but also on public-market credibility. This acquisition strategy became a major part of Matthew Schissler’s business story because it shows how he used funding, consolidation, and international expansion to build Cord Blood America into a broader cord blood banking company.
Matthew Schissler’s 2008 Business Recognition
Matthew Schissler received notable recognition in 2008 after being selected as a regional semi-finalist for the Ernst & Young Entrepreneur of the Year award in Los Angeles. The recognition came during a key growth period for CBAI, making it an important moment in his professional career. Ernst and Young’s Entrepreneur of the Year program is one of the respected business award programs in the United States, so the semi-finalist status added credibility to Schissler’s public business profile.
It also showed that his leadership, company growth, and entrepreneurial work were being noticed beyond the cord blood banking industry. In a net worth article, this recognition is useful because it shows that his business achievements were acknowledged outside his own companies.
Matthew Schissler’s Las Vegas Move and CBAI Exit
Matthew Schissler made an important business move during his time at CBAI by relocating the company’s headquarters to Las Vegas, Nevada. The move appears to have been driven by practical business reasons, including Nevada’s favorable tax structure, lower operating costs, better business accessibility, and the infrastructure Las Vegas could offer compared to California.
By 2012, after spending nine years building CBAI through acquisitions, international expansion, and major capital raises, Schissler stepped down from his Chairman and CEO roles. This exit marked a shift in his wealth strategy, moving away from single-company leadership and toward board roles, investment management, portfolio diversification, and a broader model of long-term wealth creation.
Read More: Isaac Avett: Fascinating Look Into Jennifer Carpenter’s Son’s Private Life
Matthew Schissler’s Investment and Advisory Career
After leaving CBAI, Matthew Schissler moved into a new phase focused on investments, advisory work, and board roles. Instead of leading one operating company, he began building influence through a broader portfolio of investment vehicles and business relationships.
His post-CBAI career included work with small-cap and mid-cap companies, where he used his experience in company building, strategy, and management. This shift toward portfolio management, private investment, and advisory roles shows how Schissler continued growing his business profile while creating a more diversified wealth strategy.
Matthew Schissler’s Role in Pyrenees Investments
Matthew Schissler serves as Managing Member of Pyrenees Investments LLC, a private consulting firm that supports small-cap and public company clients. Through the Pyrenees, he helps companies set up operations, build sales and marketing functions, manage compliance, and keep proper books and records. He also connects clients with legal, accounting, and finance professionals through his business network.
The firm works with more than a dozen small-cap clients at the same time, which gives Schissler a diversified consulting model instead of depending on one company’s performance. This makes Pyrenees Investments an important part of his post-CBAI career and net worth story because it creates advisory income, business relationships, and long-term service-based revenue.
Matthew Schissler’s Work Your Core Investment Strategy
Matthew Schissler’s Work Your Core Investment Strategy is centered on Work Your Core Investments LLC, a private investment vehicle he founded to support companies with strong growth potential. Instead of focusing on short-term trading, the firm appears to follow a long-term value creation approach built around private company investment, capital deployment, and business growth opportunities. Schissler’s role is also strengthened by his securities licenses, including Series 63 and Series 79, which qualify him as a registered securities professional and investment banking professional.
These credentials are important because the Series 79 license allows work in areas such as mergers and acquisitions advisory, private placements, capital markets activity, and other investment banking transactions. This makes Work Your Core Investments part of his wider net worth story because it shows a more structured investment strategy based on professional licensing, private capital, and long-term business value.
Matthew Schissler’s GHS Ownership Stake
Matthew Schissler reportedly holds about a 33 percent ownership stake in GHS Investments, which makes the firm an important part of his wider investment and net worth profile. GHS focuses on small-cap convertible note investments, a type of financing where loans made to smaller companies can later convert into equity under agreed conditions. This kind of structure is common in early-stage and small-cap financing because it gives companies access to capital while giving investors possible equity upside.
Schissler’s stake matters because it connects him to a specialized investment model built around small-cap funding, convertible debt, and long-term financial exposure. In simple terms, GHS Investments adds another layer to his wealth story by showing his involvement in equity-linked private investment beyond traditional company ownership.
Board Role at Aztec Airways
Matthew Schissler’s board role at Aztec Airways Inc. shows that his business influence reaches beyond healthcare and biotech. As a member of the Board of Directors at this regional private aviation company, he brings strategic value, executive experience, and advisory insight to another industry. This position also strengthens his professional reputation because it reflects cross-industry trust, not just a title. His connection with Aztec Airways highlights his wider business diversification and shows how his leadership role extends into the aviation sector.
Big League Wiffle Ball Explained
Big League Wiffle Ball stands out in Matthew Schissler’s board portfolio because it is different from his usual business roles. Instead of healthcare, biotech, or traditional investment sectors, this role connects him with an organized Wiffle ball league built around adult recreational sports.
Schissler serves as a Board Member, giving him a private company role in a sports venture with early-stage growth potential. This makes Big League Wiffle Ball more than just a recreational league; it shows how his investment philosophy can also target unique, growth-oriented companies with public interest and business appeal.
Frozen Food Gift Group Overview
Frozen Food Gift Group was one of Matthew Schissler’s more unusual business moves because it took him outside healthcare and into the specialty food market. In 2009, he co-founded the company with a partner, and it later traded publicly on the OTCBB under the ticker FROZ. The business focused on shipping specialty ice cream gifts across the United States, making it part of the consumer gifting and direct-to-consumer food market.
Schissler held about 36 percent ownership and also served on the Board of Directors, showing both financial involvement and operational interest. This venture highlighted his willingness to invest capital and business experience in completely different product categories.
Inside China Stem Cells Inc
Matthew Schissler’s role at China Stem Cells Inc. shows how his biotech experience moved beyond the U.S. market. He served as President of the company while also holding a minority shareholder position and working as an advisor. This role connected him directly with the stem cell industry in China and reflected his leadership in healthcare biotechnology.
It also showed how his technical and regulatory knowledge from CBAI could be applied in a different geographic market. By applying that background at China Stem Cells Inc., Schissler moved his biotech experience into international advisory work and the Chinese stem cell market.
IIOT-OXYS Inc. and Schissler’s Tech Role
Matthew Schissler’s role as Director of IIOT-OXYS Inc. shows his move into the technology sector beyond biotech. The company works in industrial Internet of Things, industrial sensors, and health monitoring technology, which connects industrial systems with healthcare monitoring needs.
This board role gives Schissler a clear place in a growth-oriented tech company and reflects his interest in businesses where technology, healthcare, and data-driven monitoring overlap. It also shows a practical biotech-to-tech crossover in his wider business profile.
Matthew Schissler Net Worth 2026 and Business Wealth
Matthew Schissler’s net worth in 2026 is best estimated between $5 million and $10 million. This range gives a more realistic picture because it is based on public career information, known investment activity, and available business records. Some sources suggest higher figures, including $20 million, but those claims are hard to verify without public financial disclosures or a Forbes profile.
Schissler has spent more than two decades as an investor and entrepreneur in private markets, small-cap companies, equity positions, capital raising, and advisory work. Since there is no clear evidence of one major liquidity event, the $5 million to $10 million range is the safer and more defensible estimate.
Full Earnings Breakdown:
| Income Source | How It May Contribute |
| Pyrenees Investments consulting fees | Advisory fees from more than a dozen small-cap business clients |
| Work Your Core Investments LLC | Investment returns from portfolio companies and private business holdings |
| GHS Investments equity stake | Returns linked to his reported 33% stake and small-cap convertible note activity |
| Aztec Airways board role | Board member fees and possible equity-based compensation |
| Big League Wiffle Ball board role | Board compensation for his involvement as a board member |
| IIOT-OXYS directorship | Director’s compensation from his role with the technology company |
| China Stem Cells advisory role | Advisory fees and possible equity interest from biotech-related work |
| Frozen Food Gift Group ownership | Returns tied to his reported 36% equity position |
| CBAI legacy value | Possible retained equity or deferred compensation from his nine-year CEO tenure |
| Series 79 investment banking license | Eligibility for transaction-based investment banking fees |
Why His Net Worth Remains an Estimate
Matthew Schissler’s net worth remains an estimate because most of his financial activity appears tied to private investments, private fund management, board advisory roles, and personal business assets. These areas usually do not require full public financial disclosure, so they cannot show his total net worth clearly. SEC Form 4 filings may track insider transactions at public companies connected to him, but they do not reveal private fund performance, personal assets, or complete wealth data.
That is why the five to ten million dollar estimate is the safer range, based on known positions, career compensation, industry benchmarks, and his type of work. His net worth could be higher, but without stronger public disclosure, any larger number remains unconfirmed.
Matthew Schissler’s Business Journey
Matthew Schissler’s business journey stands out because he built his career around opportunities that many people noticed only later. He was not chasing fame, Forbes lists, or glamorous industries; he focused on smaller markets where timing, execution, and access mattered more. His biotech phase showed how he could raise capital, consolidate a niche healthcare market, and build investor confidence around an emerging medical service.
Over time, he moved into frozen food gifting, South American biotech, Chinese stem cells, regional aviation, and adult recreational sports leagues, showing a pattern of practical business diversification. His CBAI years became the clearest example of how he entered niche markets before wider investor attention arrived. Taken together, his career shows a small-cap investor and operator who builds real businesses before the broader market fully pays attention.
Career Milestones
| Year | Career Milestone |
| 1971 | Born on June 9 |
| 1989–1993 | Earned a BA in Biology and Public Policy from St. Mary’s College of Maryland |
| 1993–1994 | Started his early career in sales at Delmarva Broadcasting |
| 1994–2001 | Worked in management and sales at TMP Worldwide, rising to Senior Regional Director |
| April 2001 | Founded RainMakers International, a direct response advertising company |
| January 2003 | Founded Cord Blood America Inc. (CBAI) and served as Chairman and CEO |
| 2005 | Led CBAI’s acquisition of Cord Partners Inc. |
| 2006 | Led CBAI’s acquisition of Cryobank for Oncologic and Reproductive Donors |
| 2006 | Added CorCell Inc., making CBAI the fourth-largest cord blood bank in the United States |
| 2007–2010 | Expanded CBAI through BioCells Argentina and raised more than $30 million in total funding |
| 2008 | Became a semi-finalist for the Ernst & Young Entrepreneur of the Year award in Los Angeles |
| 2009 | Co-founded Frozen Food Gift Group (FROZ) and held a reported 36% ownership stake |
| 2012 | Left his Chairman and CEO roles at CBAI. |
| 2012–2013 | Served as Managing Member of Pyrenees Investments LLC |
| Ongoing | Founded Work Your Core Investments LLC |
| Ongoing | Serves as a board member for Aztec Airways Inc., Big League Wiffle Ball, and IIOT-OXYS |
| Ongoing | Holds a reported 33% stake in GHS Investments |
| Ongoing | Serves as President and advisor of China Stem Cells Inc. |
| 2026 | Estimated net worth ranges from $5 million to $10 million, with activity across multiple investment vehicles |
Conclusion
Matthew L. Schissler’s career is best understood as a long record of spotting business opportunities before they became obvious. He entered direct response advertising early, moved into cord blood banking before most families knew the concept, and later expanded into South American biotech, regional aviation, sports, technology, and healthcare-related ventures. His work was never built around fame, Forbes lists, or one viral business moment; it was built around patient execution in smaller markets where valuations were still accessible, and upside potential was real.
His career shows a pattern of patient capital deployment, early market entry, and long-term business positioning across overlooked sectors. His Series 79 investment banking license adds credibility because it connects him to capital raising and advisory work for small-cap companies. That is why his estimated 2026 net worth of $5 million to $10 million looks more like the result of 25 years of disciplined investing, quiet business building, and practical market experience than one large public exit.
Frequantely Asked Questions(FAQ;s)
What is Matthew Schissler’s net worth in 2026?
Matthew Schissler’s net worth in 2026 is estimated between $5 million and $10 million. This range is based on his private investment activity, advisory work, board roles, reported GHS Investments stake, and past leadership at Cord Blood America. Higher figures appear online, but they are hard to confirm without full public financial disclosures.
Why is Matthew Schissler’s net worth only an estimate?
His net worth is only an estimate because much of his wealth appears tied to private companies, private funds, board roles, and advisory income. These types of financial activities are generally not subject to complete public reporting. SEC filings may show some public company activity, but they do not reveal his complete personal assets or private fund performance.
What is Cord Blood America?
Cord Blood America Inc., also known as CBAI, was a cord blood banking company that Matthew Schissler co-founded in January 2003. The company focused on collecting, processing, and storing umbilical cord blood stem cells for families. Schissler served as Chairman and CEO for about nine years.
What did Matthew Schissler do at Cord Blood America?
Matthew Schissler helped build Cord Blood America through fundraising, acquisitions, and market expansion. Under his leadership, the company raised more than $30 million, completed several acquisitions, and expanded into South America through BioCells Argentina. CBAI also acquired CorCell Inc., which was described as one of the largest U.S. cord blood banks at the time.
Where did Matthew Schissler go to college?
Matthew Schissler attended St. Mary’s College of Maryland between 1989 and 1993. He earned a Bachelor of Arts in Biology and Public Policy. That background helped connect his later work in biotech, healthcare, business regulation, and public company leadership.
What companies is Matthew Schissler connected with?
Matthew Schissler is connected with several companies, including Cord Blood America, Work Your Core Investments LLC, Pyrenees Investments LLC, GHS Investments, Aztec Airways Inc., Big League Wiffle Ball, IIOT-OXYS Inc., China Stem Cells Inc., and Frozen Food Gift Group. These roles show his activity across biotech, finance, aviation, technology, food gifting, and sports business.
What is Work Your Core Investments LLC?
Work Your Core Investments LLC is one of Matthew Schissler’s investment-related business entities. It is part of his wider private investment profile and appears connected to portfolio company activity. It helps explain how his wealth may come from private business holdings, not only salary or public company roles.
What is Pyrenees Investments LLC?
Pyrenees Investments LLC is another investment and advisory company linked to Matthew Schissler. He has been described as the Managing Member. The company is connected with small-cap public company advisory work, which may produce consulting fees and business income.
What is GHS Investments?
GHS Investments is a small-cap investment firm connected to Matthew Schissler through a reported 33 percent ownership stake. The firm is associated with small-cap convertible note investment activity. This stake is one reason his wealth profile is often tied to private markets and small-cap investing.
What is Matthew Schissler’s role at Aztec Airways?
Matthew Schissler serves on the Board of Directors of Aztec Airways Inc., a regional aviation company. This board role shows his business activity outside healthcare and biotech. It also supports the idea that his career includes cross-industry advisory and investment work.
What is Big League Wiffle Ball in Matthew Schissler’s career?
Big League Wiffle Ball is one of the more unusual entries in Matthew Schissler’s board portfolio. He serves as a Board Member, connecting him with an organized adult recreational sports league. This role shows his interest in early-stage and growth-oriented business opportunities outside traditional sectors.
What is China Stem Cells Inc.?
China Stem Cells Inc. is a stem cell-related company where Matthew Schissler served as President, minority shareholder, and advisor. This role extended his biotech experience into the Chinese market. It also showed how his technical and regulatory knowledge from CBAI could apply in a different business environment.
What is IIOT-OXYS Inc.?
IIOT-OXYS Inc. is a company focused on industrial Internet of Things, industrial sensors, and health monitoring technology. Matthew Schissler served as a Director there. This role connects his biotech background with technology, healthcare monitoring, and growth-oriented tech companies.
What securities licenses does Matthew Schissler hold?
Matthew Schissler has been linked with Series 63 and Series 79 securities licenses. The Series 79 license is especially important because it relates to investment banking activity. It may qualify him for transaction advisory work, capital raising, and investment banking-related business services.
Is Matthew Schissler a billionaire?
No reliable public information shows Matthew Schissler as a billionaire. A more defensible estimate places his net worth between $5 million and $10 million in 2026. Without major public disclosures or evidence of a large liquidity event, billionaire claims would not be credible.
Why do some websites confuse Matthew Schissler with another person?
Some websites confuse Matthew L. Schissler, the business executive and investor, with another Matthew Schissler, who is connected to acting and film production. This article focuses on Matthew L. Schissler, the biotech entrepreneur, small-cap investor, and private business advisor.
Why is Matthew Schissler’s career interesting?
Matthew Schissler’s career is interesting because he often entered overlooked markets before they became widely understood. His work spans direct response advertising, cord blood banking, micro-cap biotech, frozen food gifting, Chinese stem cells, regional aviation, technology, and recreational sports. That pattern shows a career built around early opportunity spotting and business diversification.
Read More: Charles Quincy Ascher Einstein: A Remarkable Family Legacy and Innovation
SEO specialist with 5+ years of experience in On-Page, Technical, and Off-Page SEO. I help websites and e-commerce stores rank higher on Google and drive consistent organic traffic through strategic SEO and keyword optimization.